Efficacy and Safety of 0.01% Atropine Eye Drops and Novel Lenslet-ARray-Integrated Spectacle Lenses for the Prevention of Myopia Progression Among Children with Premyopia: A Randomized Clinical Trial
Randomized trial demonstrates reduced myopia progression in children with premyopia using atropine and lenslet-array spectacles, indicating effective preventive measures.
Key Points
Treatment with 0.01% atropine reduced myopia progression by 55.88% among children with premyopia.
The incidence of fast myopic shift was significantly lower in treatment groups compared to controls after 12 months.
This was a prospective randomized controlled trial involving 400 children aged 6-12 years evaluated for myopic shift.
These findings suggest effective short-term interventions for myopia prevention, though long-term efficacy remains uncertain.